Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Bank of Montreal Can

Bank of Montreal Can reduced its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 0.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 132,318 shares of the company’s stock after selling 619 shares during the quarter. Bank of Montreal Can’s holdings in Apellis Pharmaceuticals were worth $5,358,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of APLS. Future Financial Wealth Managment LLC acquired a new stake in Apellis Pharmaceuticals in the first quarter valued at approximately $29,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Apellis Pharmaceuticals in the first quarter valued at $89,000. nVerses Capital LLC grew its holdings in Apellis Pharmaceuticals by 300.0% during the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after purchasing an additional 2,100 shares in the last quarter. CWM LLC grew its holdings in Apellis Pharmaceuticals by 299.9% during the 2nd quarter. CWM LLC now owns 4,151 shares of the company’s stock valued at $159,000 after purchasing an additional 3,113 shares in the last quarter. Finally, CWA Asset Management Group LLC purchased a new stake in Apellis Pharmaceuticals during the 4th quarter worth $205,000. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Price Performance

Shares of APLS opened at $27.74 on Wednesday. Apellis Pharmaceuticals, Inc. has a one year low of $26.96 and a one year high of $73.80. The stock’s fifty day moving average is $36.84 and its 200-day moving average is $42.30. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.18 and a current ratio of 5.08. The firm has a market capitalization of $3.37 billion, a price-to-earnings ratio of -8.02 and a beta of 0.88.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.03. The firm had revenue of $199.70 million for the quarter, compared to analysts’ expectations of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. Apellis Pharmaceuticals’s quarterly revenue was up 110.2% on a year-over-year basis. During the same quarter last year, the company earned ($1.02) EPS. Equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.34 EPS for the current year.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares in the company, valued at $3,623,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on APLS. Wells Fargo & Company decreased their price objective on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an “equal weight” rating for the company in a research report on Tuesday, September 24th. Robert W. Baird lowered their price objective on Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating for the company in a research note on Monday, September 23rd. The Goldman Sachs Group lifted their price objective on Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a “buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. reduced their target price on Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a research note on Friday, September 13th. Finally, Wedbush lifted their price target on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $70.20.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).